Fate Therapeutics, Inc. announced that Brian T. Powl has been appointed Chief Commercial Officer. Mr. Powl brings to Fate Therapeutics extensive commercial leadership experience in hematologic malignancies and solid tumors, having previously served as the Global Commercial CAR T lead at Celgene Corporation where he oversaw the commercial development strategy of the company's CAR T-cell therapies. Mr. Powl most recently served as Senior Vice President, Commercial Development & Marketing at MEI Pharma, Inc., where he led the commercialization efforts of a late-stage small molecule program in B-cell malignancies across marketing, sales, market access and commercial operations.

Prior to MEI Pharma, Mr. Powl was Vice President, Global Commercial CAR T lead at Celgene Corporation, where he oversaw a global portfolio of new cell therapy products, including the commercialization of the CD19- and BCMA-targeted CAR T-cell therapy programs. During his tenure at Celgene, Mr. Powl also held various senior level positions, including leading their multiple myeloma franchise in which he led the marketing of Revlimid and Pomalyst as well as their global commercial operations group for oncology products outside the United States. Prior to Celgene, Mr. Powl held sales and marketing positions at Novartis Oncology and Centocor, Inc.Mr. Powl holds a BS in Biochemistry from the University of California, San Diego and an MBA in Healthcare Management/Marketing from the Wharton School at the University of Pennsylvania.